Print

Shareholder-friendly measures to promote liquidity

2005-02-03

"The aim of these measures is to provide shareholders with uneven trading lots with the possibility of divesting or acquiring shares without cost, thus establishing a more active shareholder base. Combined with the liquidity provision agreement, this will generate improved liquidity for the Active Biotech share," says Sven Andréasson, President & CEO of Active Biotech.
Active Biotech offers commission-free trading
The Board of Active Biotech has decided to offer the company's shareholders commission-free purchase or sale of the number of shares required for an individual shareholder to acquire a holding corresponding to a trading lot (200 shares). The offer is being handled by Swedbank and will be available during the period February 28 through March 11, 2005. The goal of the offering is to increase the number of shareholders owning a round lot, thus creating improved liquidity for the Active Biotech share.
Active Biotech signs agreement with Swedbank for liquidity provision
Active Biotech has signed an agreement under which Swedbank will be a liquidity provider for Active Biotech's shares. The aim is to increase liquidity in the company's shares. In brief, the agreement means that Swedbank will set buy and sell prices for Active Biotech's share listed on the O List, Attract 40, of the Stockholm Stock Exchange and undertakes to buy and sell shares at these prices on its own account. The agreement will apply from February 7, 2005.
Lund, February 3, 2005
Active Biotech AB (publ)
Sven Andréasson
President and CEO
For further information, please contact:
Active Biotech AB
Sven Andréasson, President & CEO, +46 (0)46 19 20 00
Hans Kolam, CFO, +46 (0)46 19 20 44
FöreningsSparbanken / Swedbank AB
Hans Westerberg, Equity Capital Markets, tel. +46 (0)8 585925 11,
+46 (0)706 09 25 11
Information about Active Biotech and the offer are available at www.activebiotech.com.
Active Biotech AB is a biotechnology company focusing on research in and development of pharmaceuticals. Active Biotech has a strong research portfolio and pipeline products with focus primarily on autoimmune/inflammatory diseases and cancer. Most advanced projects involve unique substances with immunomodulatory properties intended for the treatment of diseases including multiple sclerosis, as well as a novel concept for the treatment of cancer (TTS).
Active Biotech AB
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 20 50

pdf



Back